Disclosures for "Inhibition of TNFalpha Release by Purine Nucleosides in a Human Monocyte-derived Microglial Model Exhibits Apparent Insensitivity to Adenosine, P2X, and P2Y Receptor Antagonism"
-
Dr. Qureshi has received personal compensation for serving as an employee of Celentyx Ltd. Dr. Qureshi has received personal compensation for serving as an employee of UCB Pharma. Dr. Qureshi has stock in Celentyx.
-
Mr. Cowley has received personal compensation for serving as an employee of Celentyx Ltd.
-
Miss Kaur has received personal compensation for serving as an employee of Celentyx.Ltd.
-
Mr. Pegg has received personal compensation for serving as an employee of Celentyx Ltd.
-
Ms. Sallie has received personal compensation for serving as an employee of Celentyx.
-
Ms. Morano has received personal compensation for serving as an employee of Celentyx Ltd..
-
Dr. Harrison has received personal compensation for serving as an employee of Celentyx Ltd.
-
Mr. Chan has received personal compensation for serving as an employee of Celentyx.
-
Dr. Li has received personal compensation for serving as an employee of Celentyx Ltd.
-
Miss Welsh has received personal compensation for serving as an employee of Celentyx.
-
Dr. Bryant has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Celentyx Ltd.
-
Dr. Brady has received personal compensation for serving as an employee of Celentyx Ltd.
-
Prof. Gordon has received personal compensation for serving as an employee of Celentyx Ltd.
-
Prof. Barnes has received personal compensation for serving as an employee of Celentyx Ltd. Prof. Barnes has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers. Prof. Barnes has stock in Celentyx Ltd. The institution of Prof. Barnes has received research support from MRC.